Shopping Cart
Remove All
Your shopping cart is currently empty
BPO-27 racemate (BPO-27 (racemate)) is an effective CFTR inhibitor with IC50 of 8 nM.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $39 | In Stock | In Stock | |
| 5 mg | $119 | In Stock | In Stock | |
| 10 mg | $178 | In Stock | In Stock | |
| 25 mg | $295 | In Stock | In Stock | |
| 50 mg | $431 | In Stock | In Stock | |
| 100 mg | $595 | In Stock | In Stock | |
| 200 mg | $798 | In Stock | In Stock | |
| 1 mL x 10 mM (in DMSO) | $137 | In Stock | In Stock |
| Description | BPO-27 racemate (BPO-27 (racemate)) is an effective CFTR inhibitor with IC50 of 8 nM. |
| Targets&IC50 | CFTR:8 nM |
| In vitro | The R enantiomer of BPO-27 inhibits CFTR chloride conductance (IC50: 4 nM), while S enantiomer is inactive. In vitro metabolic stability in hepatic microsomes shows both enantiomers as stable, with less than 5% metabolism in 4 h [1]. (R)-BPO-27 binds near the canonical ATP binding site. Whole-cell patch-clamp studies show linear CFTR currents with a voltage-independent (R)-BPO-27 block mechanism. At a concentration of (R)-BPO-27 that inhibits CFTR chloride current by 50%, the EC50 for ATP activation of CFTR increases from 0.27 to 1.77 mM [2]. |
| In vivo | Following bolus intraperitoneal administration of BPO-27 in mice, serum (R)-1 decays with t1/2 ≈ 1.6 h and gives sustained therapeutic concentrations in the kidney [1]. |
| Synonyms | BPO-27 (racemate) |
| Molecular Weight | 548.34 |
| Formula | C26H18BrN3O6 |
| Cas No. | 1314873-02-3 |
| Smiles | Cn1c2c3C(Oc4ccc(cc4-n3c(-c3ccccc3)c2c(=O)n(C)c1=O)C(O)=O)c1ccc(Br)o1 |
| Relative Density. | 1.68 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 55 mg/mL (100.3 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+90% Corn Oil: 1.67 mg/mL (3.05 mM), Sonication is recommeded. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.